The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada

Table 1

Baseline characteristics of 100 men referred for androgen deprivation therapy.

Age at diagnosis	73 (50–87)
Vascular disease	25 (25%)
Coronary artery disease	17 (17%)
Percutaneous coronary intervention	9 (9%)
Coronary artery bypass surgery	5 (5%)
Stroke	7 (7%)
Peripheral arterial disease	5 (5%)
Atrial fibrillation	5 (5%)
Supraventricular tachycardia	1 (1%)
Arrhythmia, not specified	4 (4%)
Cardiac pacemaker	1 (1%)
Pericarditis	1 (1%)
Coronary vasospasm	1 (1%)
History of heart failure	1 (1%)
Framingham risk category
High risk	49 (65%)^*
Intermediate risk	25 (33%)^*
Low risk	1 (1%)^*
Gleason score
Moderately differentiated (5–7)	30 (30%)
Poorly differentiated (8–10)	70 (70%)
Clinical stage
T1	27 (27%)
T2	43 (43%)
T3	23 (23%)
T4	3 (3%)
X	4 (4%)
Initial PSA (ng/mL)
<5	9 (9%)
5–10	29 (29%)
>10	62 (62%)
Updated Charlson Comorbidity Index
0	82 (82%)
1	14 (14%)
≥2	4 (4%)
Hormonal treatment used
Goserelin	72 (72%)
Leuprolide	25 (25%)
Degarelix	2 (2%)
Bicalutamide	92 (92%)
Buserelin	1 (1%)
Flutamide	1 (1%)

Expressed as median (range) or number (percentage).
^*Expressed as percentage of patients without baseline history of vascular disease.